Codex_V5

Mutant	Gene	Virus	Reference
N498S	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
N498S	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
N498S	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D515E	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D515E	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D515E	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D542E	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D542E	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D542E	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A543V	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A543V	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A543V	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A786V	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A786V	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A786V	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A928T	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A928T	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
A928T	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
E949K	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
E949K	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
E949K	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
E949Q	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
E949Q	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
E949Q	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D981del2	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D981del2	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
D981del2	UL54	Human betaherpesvirus 5	A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
S229Y	UL56	Human betaherpesvirus 5	Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
V231L	UL56	Human betaherpesvirus 5	Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
M329I	UL56	Human betaherpesvirus 5	Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
F342Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
F342Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L397R	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L397R	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
T409M	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
T409M	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
H411Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
H411Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
M460I	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
M460I	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
M460V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
M460V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C480F	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C480F	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
H520Q	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
H520Q	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C592G	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C592G	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594P	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594P	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
A594V	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595F	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595F	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595S	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595S	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595W	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
L595W	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C603W	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C603W	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C603Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
C603Y	UL97	Human betaherpesvirus 5	Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)